Synta Pharmaceuticals Corporation

Fuji Photo Film Company, Limited

Alps Pharmaceutical Ind. Co., Ltd.

Shionogi Bioresearch Corporation

Other

The Frs Company

Fuji Immunopharmaceuticals Corp.

Kava Pharmaceuticals, Inc.

Flaxan Gmbh & Co. Kg

Quercegen Pharma LLC

Flazan Gmbh & Co. Kg

New Sun Nutrition LLC

Quercegen Holdings LLC

Shiongi Bioresearch Corp.

Mitsunori Ono

Lijun Sun

Keizo Koya

Yumiko Wada

Shoujun Chen

Noriaki Tatsuta

Teresa Przewloka

Isamu Itoh

Naoto Yamaguchi

Lan Bo Chen

Thomas Christian Lines

Koji Tamoto

Yu Xie

Yaming Wu

Weiwen Ying

Elena Kostik

Zhi-Qiang Xia

Keiji Mihayashi

Hao Li

Zachary Demko

Naoyuki Nishikawa

Seiji Ichijima

Howard P Ng

Shijie Zhang

David James

Wojciech Wrona

Morio Yagihara

Hidetoshi Kobayashi

Sylvia Holden

Hiroaki Kida

Toshiaki Aoai

Nobuo Suzuki

Stephen D Gillies

Dinesh U Chimmanamada

Hideto Mori

Hiroshi Kitaguchi

Jun Jiang

Akihiko Ikegawa

Yoshisada Nakamura

Natalie Alysia Dales

Tsutomu Miyasaka

Dan Zhou

Guiqing Liang

Kazuyoshi Yamakawa

Yuniko Wada

Xueliang Tao

Tadashi Ikeda

Yoshio Inagaki

Shigeo Hirano

Koki Nakamura

Yuji Mihara

Kin-Ming Lo

Yoshihisa Tsukada

Shingo Sato

Zhenjian Du

Shoji Ishiguro

Toshiro Takahashi

Nobuhito Masuda

Yukio Karino

Noboru Sasaki

Ichiro Azuma

Hiroshi Shinoki

Ken-ichi Kuwabara

Masayoshi Kojima

Ryoichi Nemori

Hideaki Satoh

Hiroyuki Komazawa

Chih-Yi Yu

Mats Harald Holmqvist

Jerome Mahiou

Atsushi Orikasa

Ikuo Saiki

Y-s Edmond Cheng

Wenli Ding

Yui Sudaka

Nha Huu Vo

Tadeusz Warchol

Keiko Yamaguchi

Yumiko Jimbo

Hiroshi Kataguchi

Douglas F Marks, Jr

Timothy Korbut

Keizo Kova

K Koya

Elena Kostic

Jifeng Duan

Beatrice Brunkhorst

A composition containing L-arginine and a glycosyl compound of formula (I): 

Compositions of O-glycosyl flavonoids

A water-soluble composition including an O-glycosyl flavonoid compound, L-arginine, a sugar alcohol, and ascorbic acid or an alkali salt of ascorbic acid. The O-glycosyl flavonoid compound is rutin, isoquercitrin, or hesperidin, and a molar ratio between the O-glycosyl flavonoid compound and the sugar alcohol is 1:4.0-12.0. Also provided is a method for making the above-described water-soluble composition by combining the O-glycosyl flavonoid compound, L-arginine, the sugar alcohol, and ascorbic acid or an alkali salt thereof to form a mixture, and heating it at 110&#xb0; C.-140&#xb0; C. to melt the mixture.

Water soluble O-glycosyl flavonoid compositions and methods for preparing same

A water-soluble composition containing rutin, L-arginine, and an alkali salt of ascorbic acid in which the molar ratio between the rutin, L-arginine, and the alkali salt of ascorbic acid is 1:1.6-3.0:0.1-2.0.

Rutin compositions

A water-soluble pharmaceutical composition containing isoquercitrin, L-arginine, and ascorbic acid or an alkali salt thereof, in which the molar ratio between the isoquercitrin, L-arginine, and the ascorbic acid or alkali salt is 1:1.6-2.6:0.16-1.95.

Isoquercitrin compositions

Disclosed is a compound represented by the Structural Formula (I):  Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

Paclitaxel enhancer compounds

The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone.

Compositions containing xanthohumol-cyclodextrin complexes

This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.

Composition for enhancing physical performance

This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.

Fused hetrocyclic compounds

This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.

Pyridine compounds

A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for treating various diseases, e.g., skin disorders, and bacterial infection.

Xanthohumol-enriched hop extract

This invention relates to compounds having a formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, prodrug or polymorph thereof wherein X is &#x2014;C(R)&#x2550;N-A. The invention also relates to methods of treating IL-12 overproduction-related disorders, methods of treating or preventing disorders related with excessive bone loss, methods for inhibiting osteoclast formation, and methods for treating or preventing a disorder associated with excessive bone resorption.

Heteroaryl-hydrazone compounds

One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by Structural Formula (I): 

Treatment for cancers

One embodiment of the present invention is a compound represented by the Structural Formula (I):  Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.

Paclitaxel enhancer compound

Growing community of inventors

Lexington, MA, United States of America

Mitsunori Ono